DS
AEGR

David Shaw’s Aegerion Pharmaceuticals AEGR Stock Holding History

David Shaw’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-94,400
Closed -$3.15M – 4438
2014
Q3 		$3.15M Sell
94,400
-11,500
-11% -$357K ﹤0.01% 1881
2014
Q2 		$3.4M Sell
105,900
-46,600
-31% -$1.74M ﹤0.01% 1894
2014
Q1 		$7.03M Sell
152,500
-39,100
-20% -$2.29M 0.01% 1299
2013
Q4 		$13.6M Sell
191,600
-8,800
-4% -$673K 0.02% 916
2013
Q3 		$17.2M Buy
200,400
+142,600
+247% +$12.1M 0.03% 665
2013
Q2 		$3.66M Buy
+57,800
New +$3.07M 0.01% 1589

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 30.2% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

David Shaw's AEGR Position: Q4 2015 in Review

David Shaw sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2015, closing a stake of 31,116 shares — an estimated $423K sold.

David Shaw first reported a position in AEGR in Q2 2013 and held it in 10 quarters. The position peaked at $9.12M in Q3 2014. 109 funds tracked by Wall St. Rank hold AEGR as of Q4 2015.

  • David Shaw reported no remaining Aegerion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • David Shaw sold 31,116 Aegerion Pharmaceuticals shares in Q4 2015, an estimated $423K.
  • David Shaw first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
  • David Shaw's Aegerion Pharmaceuticals position peaked at $9.12M in Q3 2014.
  • 109 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2015.

Based on D.E. Shaw & Co's 13F filing for Q4 2015, filed 16 Feb 2016.